Afinitor Articles
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
3 May 2013
Growing patient population to drive Mexican breast cancer market
20 February 2013
Bayer's Nexavar continues to dominate advanced liver cancer therapy, as other late-stage trials fail
17 January 2013
US oncologists' perceptions of Roche's Perjeta very promising
7 September 2012
US FDA backs new indications for Votrient and Afinitor
29 April 2012
Breast cancer therapy news at SABCS
9 December 2011
EU approval for Janssen-Cilag’s Zytiga in prostate cancer and Novartis’ Votubia for SEGA
8 September 2011
Europe’s CHMP adopts positive opinions on Dexdor, Incivo, Plenadren, Vyndaqel and Zytiga; backs extensions
23 July 2011
US FDA panel backs Novartis’ Afinitor and Pfizer’ Sutent for rare cancer, and agency OKs Merck & Co’s Sylatron for melanoma
13 April 2011
Novartis drops Ph III Tasigna trial for GIST; in-licenses Sativex; and reports new Gilenya data
11 April 2011
Novartis’ Zometa fails to meet Ph III primary endpoint in early breast cancer, stalling this indication; but Afinitor looks good
10 December 2010
UK’s NICE not to recommend Roche’s Tarceva for NSCLC and Novartis’ Afinitor rejected for kidney cancer, with both drugmakers to appeal
26 November 2010
Novartis’ Onbrez Breezhaler beats Spiriva in new study of COPD patients; Afinitor reduces SEGAs size
4 November 2010
US FDA approves Novartis Afinitor for SEGA, Forest’s Teflaro for CABP and Avanir’s Nuedexta for PBA
1 November 2010
ASCO highlights include cancer drug news from Pfizer, Roche, Sanofi, Merck KGaA, Novartis and Eisai
7 June 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Batch of Japanese drug approvals, including for Taiho, Daiichi Sankyo and three for Novartis
20 January 2010
Novartis aims to hold global position in oncology, with new drugs and indications, R&D meeting told
9 December 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
Changes predicted in renal cell carcinoma market leaders
15 September 2009
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
Afinitor cleared in USA for advanced RCC
1 April 2009
Afinitor halts GI cancer in 55% of patients
26 January 2009
Novartis' Afinitor may overcome Herceptin resistance; Ph I study
22 December 2008
Novartis lines up aliskiren combos and cancer drugs to deal with Diovan's 2012 patent loss
24 November 2008
Novartis' RAD001 gets US priority review
15 September 2008
Showing 1-43 of 43 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
